Liquidia Corporation Announces Updates to Operations Leadership
19 janv. 2024 06h30 HE
|
Liquidia Corporation
MORRISVILLE, N.C., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today updates and promotions to its operations leadership in advance of the...
Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims
08 janv. 2024 08h22 HE
|
Liquidia Corporation
Seeks dismissal of all claims related to ‘793 patent based on prior findings of invalidity which have been affirmed by the Federal CircuitRequests declaration that ‘327 patent is not infringed, is...
Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD
05 janv. 2024 06h45 HE
|
Liquidia Corporation
Enrolled first PH-ILD patient in the open-label ASCENT study of YUTREPIAConfirmed with FDA that a single pivotal efficacy trial with L606 will support PAH and PH-ILD indications MORRISVILLE, N.C.,...
Liquidia Corporation Announces $100 Million in New Financings
04 janv. 2024 09h10 HE
|
Liquidia Corporation
Agreed to $75.0 million sale of common stock to fund affiliated with Patient Square Capital in a private placementAdditional advance of $25.0 million from HealthCare Royalty under current financing...
Liquidia Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
02 janv. 2024 06h45 HE
|
Liquidia Corporation
MORRISVILLE, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the...
U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)
20 déc. 2023 16h56 HE
|
Liquidia Corporation
Liquidia will pursue final FDA approval for YUTREPIA™ (treprostinil) inhalationLiquidia will immediately request that District Court set aside injunction tied to ‘793 patent MORRISVILLE, N.C., Dec. ...
Liquidia Announces Pricing of Public Offering of Common Stock
12 déc. 2023 07h13 HE
|
Liquidia Corporation
MORRISVILLE, N.C., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it has priced an underwritten public offering of 3,491,620 shares of common stock at a...
Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update
07 nov. 2023 06h30 HE
|
Liquidia Corporation
Oral arguments in appeal of ‘793 PTAB decision set for December 4, 2023PDUFA goal date to add PH-ILD indication to YUTREPIA label is January 24, 2024Hired sales force in preparation of potential...
Liquidia Corporation to Report Third Quarter 2023 Financial Results on November 7, 2023
31 oct. 2023 06h30 HE
|
Liquidia Corporation
MORRISVILLE, N.C., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its third quarter 2023 financial results on Tuesday, November 7, 2023....
FDA Accepts Submission to Add PH-ILD to YUTREPIA™ Label
25 sept. 2023 16h09 HE
|
Liquidia Corporation
Sets PDUFA goal date of January 24, 2024If approved, YUTREPIA would be indicated for treatment of both PAH and PH-ILD MORRISVILLE, N.C., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation...